Literature DB >> 465742

Remission induction and remission maintenance in adult acute nonlymphocytic leukemia employing a modified cytostatic (COAP) regimen.

D Gerecke, W D Hirschmann, R Voigtmann, R Gross.   

Abstract

Thirty adult patients suffering from acute nonlymphocytic leukemia (ANLL) were treated according to a modified COAP regimen. Vincristine, cyclophosphamide, and prednisone were given by push injection, while cytosine arabinoside was infused over periods of 8 h. Nineteen patients (63%) achieved complete remission. Remission maintenance therapy consisted of 6-mercaptopurine daily and methotrexate twice weekly. Later in the study, COAP consolidation and reinduction was added, which improved the median duration of complete remission from 7 to 24 months. Comparison of the results with the literature shows that the modified COAP regimen is one of the most effective treatment schedules for adult ANLL.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 465742     DOI： 10.1007/bf01008073

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


  26 in total

1.  [COAP and TRAP-combination chemotherapy in acute granulocytic Leukemias (peroxidase type) in adults].

Authors:  H Pralle; H Löffler
Journal:  Med Welt       Date:  1975-09-26

2.  [First clinical experiences with a modified COAP schedule in acute leukoses of adults].

Authors:  D Gerecke; H D Kaulen; W D Hirschmann; R Voigtmann; R Gross
Journal:  Verh Dtsch Ges Inn Med       Date:  1975

3.  Treatment of acute leukemia in adults. Results with a combination of potent cytotoxic drugs.

Authors:  P Stavem; T Gjemdal
Journal:  Acta Med Scand       Date:  1974 Jul-Aug

4.  Management of adult acute myelogenous leukaemia.

Authors:  D Crowther; R L Powles; C J Bateman; M E Beard; C L Gauci; P F Wrigley; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1973-01-20

5.  [Androgens and prolonged complete remissions in acute non lymphoblastic leukemias. Results of a systematic treatment with stanozolol associated with chemotherapy (author's transl)].

Authors:  J J Sotto; D Hollard; R Schaerer; J C Bensa; D Seigneurin
Journal:  Nouv Rev Fr Hematol       Date:  1975 Jan-Feb

6.  Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia.

Authors:  C B Freeman; R Harris; C G Geary; M J Leyland; J E MaCiver; I W Delamore
Journal:  Br Med J       Date:  1973-12-08

7.  [Clinical and cell kinetic data on the combination of cytosine arabinoside with daunorubicin, isosfamide, thioguanine, and vincristine for remission induction and maintenance in patients with acute myelocytic leukaemia (author's transl)].

Authors:  T h Büchner; D Kamanabroo; D Urbanitz; W Hiddemann; J van de Loo
Journal:  Blut       Date:  1978-06-20

8.  Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignancies.

Authors:  C Jacquillat; M Weil; M F Gemon-Auclerc; V Izrael; A Bussel; M Boiron; J Bernard
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

9.  High remission-induction rate in acute myeloid leukaemia.

Authors:  R P Gale; M J Cline
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

10.  Immunotherapy for acute myelogenous leukaemia.

Authors:  R L Powles; D Crowther; C J Bateman; M E Beard; T J McElwain; J Russell; T A Lister; J M Whitehouse; P F Wrigley; M Pike; P Alexander; G H Fairley
Journal:  Br J Cancer       Date:  1973-11       Impact factor: 7.640
View more
  2 in total

1.  Therapy for acute myeloid leukemia in 119 adults: a comparison of two treatment protocols.

Authors:  H Link; H M Frauer; P Ostendorf; H D Waller
Journal:  Blut       Date:  1985-07

2.  Long term follow-up of remission patients in adult acute leukemia.

Authors:  D Gerecke; M Kress; W D Hirschmann
Journal:  Klin Wochenschr       Date:  1983-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.